75.01
-1.03(-1.35%)
Currency In USD
Address
One Broadway
Cambridge, MA 02142
United States of America
Phone
857 357 7000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
162
First IPO Date
July 29, 2021
| Name | Title | Pay | Year Born |
| Dr. James R. Porter Ph.D. | Chief Executive Officer, President & Director | 1.08M | 1976 |
| Prof. Matthew D. Shair Ph.D. | Founder, Head of Scientific Advisory Board & Director | 241,530 | 1969 |
| Ms. Darlene Noci | Chief Development Officer | 670,104 | 1978 |
| Ms. Deborah Ann Miller J.D., Ph.D. | Chief Legal Officer & Secretary | 681,804 | 1976 |
| Ms. Alexandra Balcom CPA, M.B.A. | Chief Financial Officer & Treasurer | 706,854 | 1985 |
| Dr. Christopher D. Turner M.D. | Chief Medical Officer | 771,204 | 1969 |
| Mr. John Soglia Ph.D. | Senior Vice President of Translational Development | 0 | N/A |
| Mr. Matthew Metivier M.B.A. | Senior Vice President of Human Resources | 0 | N/A |
| Dr. Henry Pelish Ph.D. | Chief Scientific Officer | 0 | 1973 |
| Dr. Benjamin Lane Ph.D. | Senior Vice President of Technical Operations | 0 | N/A |
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.